Kinase inhibitors in prostate cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 1089-1104

  Limvorasak, Suwicha ^a   Posadas, Edwin M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; ARQ 197; BICALUTAMIDE; CANERTINIB; CEDIRANIB; DASATINIB; DOCETAXEL; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LEFLUNOMIDE; LESTAURTINIB; MP 470; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PAZOPANIB; PELITINIB; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; TAK 165; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER PAIN; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; HUMAN; INFECTION; LYMPHOCYTOPENIA; MORBIDITY; NAUSEA AND VOMITING; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TOXICITY; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; MALE; PHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 73349139202     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789735080     Document Type: Review

References (155)

1. Mariani, A.J.; Glover, M.Arita, S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J. Urol., 2001, 165(1), 104-107.
2. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N. Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.Crawford, E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med., 2004, 351(15), 1513-20.
3. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A. Eisenberger, M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 51(15), 1502-12.
4. Krause, D.S.Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med., 2005, 353(2), 172-87.
5. Van Etten, R.A. c-Abl regulation: a tail of two lipids. Curr. Biol., 2003, 13(15), R608-10.
6. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103(2), 211-25.
7. Druker, B.J.; Sawyers, C.L.; Kantarjian, H.; Resta, D.J.; Reese, S.F.; Ford, J.M.; Capdeville, R.Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344(14), 1038-42.
8. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-7.
9. Apperley, J.F.; Cortes, J.E.; Kim, D.W.; Roy, L.; Roboz, G.J.; Rosti, G.; Bullorsky, E.O.; Abruzzese, E.; Hochhaus, A.; Heim, D.; de Souza, C.A.; Larson, R.A.; Lipton, J.H.; Khoury, H.J.; Kim, H.J.; Sillaber, C.; Hughes, T.P.; Erben, P.; Van Tornout, J.Stone, R.M. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START A Trial. J. Clin. Oncol., 2009, 27(21), 3472-3479.
10. Metzelder, S.; Wang, Y.; Wollmer, E.; Wanzel, M.; Teichler, S.; Chaturvedi, A.; Eilers, M.; Enghofer, E.; Neubauer, A.Burchert, A. Compassionate-use of sorafenib in Flt3-ITD positive acute myeloid leukemia: sustained regression prior and post allogenic stem cell transplantation. Blood, 2009, 113(26), 6567-6571.
11. Keating, G.M.Santoro, A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs, 2009, 69(2), 223-40.
12. Escudier, B.; Szczylik, C.; Hutson, T.E.; Demkow, T.; Staehler, M.; Rolland, F.; Negrier, S.; Laferriere, N.; Scheuring, U.J.; Cella, D.; Shah, S.Bukowski, R.M. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27(8), 1280-9.
13. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Staehler, M.; Negrier, S.; Chevreau, C.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Anderson, S.; Hofilena, G.; Shan, M.; Pena, C.; Lathia, C.Bukowski, R.M. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J. Clin. Oncol., 2009, 27(20), 3312-3318.
14. Motzer, R.J.Bukowski, R.M. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24(35), 5601-8.
15. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356(2), 115-24.
16. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I.G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.Motzer, R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007, 356(22), 2271-81.
17. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Urbanowitz, G.; Berg, W.J.; Kay, A.; Lebwohl, D.Ravaud, A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008, 372(9637), 449-56.
18. Burstein, H.J.; Storniolo, A.M.; Franco, S.; Forster, J.; Stein, S.; Rubin, S.; Salazar, V.M.Blackwell, K.L. A phase II study of lapatinib monotherapy in chemotherapy-refractory Her-2-positive and Her-2-negative advanced or metastatic breast cancer. Ann. Oncol., 2008, 19(6), 1068-74.
19. Cho, B.C.; Im, C.K.; Park, M.S.; Kim, S.K.; Chang, J.; Park, J.P.; Choi, H.J.; Kim, Y.J.; Shin, S.J.; Sohn, J.H.; Kim, H.Kim, J.H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol., 2007, 25(18), 2528-33.
20. Ebi, N.; Semba, H.; Tokunaga, S.J.; Takayama, K.; Wataya, H.; Kuraki, T.; Yamamoto, H.; Akamine, S.J.; Okamoto, I.Nakanishi, Y. A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J. Thorac. Oncol., 2008, 3(10), 1166-71.
21. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol., 2003, 21(12), 2237-46.
22. Duda, D.G.; Batchelor, T.T.; Willett, C.G.Jain, R.K. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol. Med., 2007, 13(6), 223-30.
23. Rak, J.; Mitsuhashi, Y.; Bayko, L.; Filmus, J.; Shirasawa, S.; Sasazuki, T.Kerbel, R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 1995, 55(20), 4575-80.
24. George, D.J.; Halabi, S.; Shepard, T.F.; Vogelzang, N.J.; Hayes, D.F.; Small, E.J.Kantoff, P.W. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res., 2001, 7(7), 1932-6.
25. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64(19), 7099-109.
26. Dahut, W.L.; Scripture, C.; Posadas, E.; Jain, L.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Yu, Y.; Cao, L.; Steinberg, S.M.; Aragon-Ching, J.B.; Venitz, J.; Jones, E.; Chen, C.C.Figg, W.D. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res., 2008, 14(1), 209-14.
27. Aragon-Ching, J.B.; Jain, L.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Steinberg, S.M.; Draper, D.; Venitz, J.; Jones, E.; Chen, C.C.; Figg, W.D.Dahut, W.L. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int., 2009, 103(12), 1634-1640.
28. Chi, K.N.; Ellard, S.L.; Hotte, S.J.; Czaykowski, P.; Moore, M.; Ruether, J.D.; Schell, A.J.; Taylor, S.; Hansen, C.; Gauthier, I.; Walsh, W.Seymour, L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol., 2008, 19(4), 746-51.
29. Safarinejad, M.R. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study. Urol. Oncol., 2008.
30. Steinbild, S.; Mross, K.; Frost, A.; Morant, R.; Gillessen, S.; Dittrich, C.; Strumberg, D.; Hochhaus, A.; Hanauske, A.R.; Edler, L.; Burkholder, I.Scheulen, M. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br. J. Cancer, 2007, 97(11), 1480-5.
31. Dror Michaelson, M.; Regan, M.M.; Oh, W.K.; Kaufman, D.S.; Olivier, K.; Michaelson, S.Z.; Spicer, B.; Gurski, C.; Kantoff, P.W.Smith, M.R. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol., 2009, 20(5), 913-20.
32. Periman, P.; Sonpavde, G.; Bernold, D.; Weckstein, D.; Williams, A.; Zhan, F.; Boehm, K.; Asmar, L.Hutson, T. Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy. J. Clin. Oncol., 2008, 26 (suppl: abstr 5157).
33. Stadler, W.M.; Cao, D.; Vogelzang, N.J.; Ryan, C.W.; Hoving, K.; Wright, R.; Karrison, T.Vokes, E.E. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin. Cancer Res., 2004, 10(10), 3365-70.
34. Figg, W.D.; Hussain, M.H.; Gulley, J.L.; Arlen, P.M.; Aragon-Ching, J.B.; Petrylak, D.P.; Higano, C.S.; Steinberg, S.M.; Chatta, G.S.; Parnes, H.; Wright, J.J.; Sartor, O.; Dahut, W.L. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J. Urol., 2009, 181(3), 1104-13; discussion 1113.
35. Wedge, S.R.; Ogilvie, D.J.; Dukes, M.; Kendrew, J.; Chester, R.; Jackson, J.A.; Boffey, S.J.; Valentine, P.J.; Curwen, J.O.; Musgrove, H.L.; Graham, G.A.; Hughes, G.D.; Thomas, A.P.; Stokes, E.S.; Curry, B.; Richmond, G.H.; Wadsworth, P.F.; Bigley, A.L.Hennequin, L.F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 2002, 62(16), 4645-55.
36. Holden, S.N.; Eckhardt, S.G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M.A.; Wheeler, C.; Barge, A.Hurwitz, H.I. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol., 2005, 16(8), 1391-7.
37. Ciardiello, F.; Caputo, R.; Damiano, V.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B.M.; Fontanini, G.; Bianco, A.R.Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9(4), 1546-56.
38. Nicholson, B.; Gulding, K.; Conaway, M.; Wedge, S.R. Theodorescu, D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin. Cancer Res., 2004, 10(24), 8728-34.
39. Wedge, S.R.; Kendrew, J.; Hennequin, L.F.; Valentine, P.J.; Barry, S.T.; Brave, S.R.; Smith, N.R.; James, N.H.; Dukes, M.; Curwen, J.O.; Chester, R.; Jackson, J.A.; Boffey, S.J.; Kilburn, L.L.; Barnett, S.; Richmond, G.H.; Wadsworth, P.F.; Walker, M.; Bigley, A.L.; Taylor, S.T.; Cooper, L.; Beck, S.; Jurgensmeier, J.M.Ogilvie, D.J. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res., 2005, 65(10), 4389-400.
40. Laurie, S.A.; Gauthier, I.; Arnold, A.; Shepherd, F.A.; Ellis, P.M.; Chen, E.; Goss, G.; Powers, J.; Walsh, W.; Tu, D.; Robertson, J.; Puchalski, T.A.Seymour, L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol., 2008, 26(11), 1871-8.
41. Karakunnel, J.; Gulley, J.; Arlen, P.; Mulquin, M.; Wright, J.; Turkbey, I.; Choyke, P.; Ahlers, C.; Figg, W.Dahut, W. Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J. Clin. Oncol., 2008, 26 (Suppl), abstr 5136.
42. Wood, J.M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.H.; Schneider, M.R.; Drevs, J.; Martiny-Baron, G.Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 2000, 60(8), 2178-89.
43. Drevs, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Muller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.Marme, D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res., 2000, 60(17), 4819-24.
44. Thomas, A.L.; Morgan, B.; Horsfield, M.A.; Higginson, A.; Kay, A.; Lee, L.; Masson, E.; Puccio-Pick, M.; Laurent, D.Steward, W.P. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol., 2005, 23(18), 4162-71.
45. Ciardiello, F.Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med., 2008, 358(11), 1160-74.
46. Voldborg, B.R.; Damstrup, L.; Spang-Thomsen, M.Poulsen, H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol., 1997, 8(12), 1197-206.
47. Harari, P.M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer, 2004, 11(4), 689-708.
48. MacDonald, A.Habib, F.K. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br. J. Cancer, 1992, 65(2), 177-82.
49. Di Lorenzo, G.; Tortora, G.; D'Armiento, F.P.; De Rosa, G.; Staibano, S.; Autorino, R.; D'Armiento, M.; De Laurentiis, M.; De Placido, S.; Catalano, G.; Bianco, A.R.Ciardiello, F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res., 2002, 8(11), 3438-44.
50. Vicentini, C.; Festuccia, C.; Gravina, G.L.; Angelucci, A.; Marronaro, A.Bologna, M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J. Cancer Res. Clin. Oncol., 2003, 129(3), 165-74.
51. Sirotnak, F.M.; She, Y.; Lee, F.; Chen, J.Scher, H.I. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin. Cancer Res., 2002, 8(12), 3870-6.
52. Pezaro, C.; Rosenthal, M.A.; Gurney, H.; Davis, I.D.; Underhill, C.; Boyer, M.J.; Kotasek, D.; Solomon, B.Toner, G.C. An openlabel, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am. J. Clin. Oncol., 2009.
53. Canil, C.M.; Moore, M.J.; Winquist, E.; Baetz, T.; Pollak, M.; Chi, K.N.; Berry, S.; Ernst, D.S.; Douglas, L.; Brundage, M.; Fisher, B.; McKenna, A.Seymour, L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol., 2005, 23(3), 455-60.
54. Boccardo, F.; Rubagotti, A.; Conti, G.; Battaglia, M.; Cruciani, G.; Manganelli, A.; Ricci, S.Lapini, A. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology, 2008, 74(3-4), 223-8.
55. Curigliano, G.; De Braud, F.; Teresa Sandri, M.; Renne, G.; Zorzino, L.; Scardino, E.; Rocco, B.; Spitaleri, G.; De Pas, T.; Noberasco, C.; Nole, F.; Verweij, F.; Matei, V.De Cobelli, O. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Anticancer Drugs, 2007, 18(8), 949-54.
56. Curigliano, G.; Spitaleri, G.; De Cobelli, O.; Scardino, E.; Sbanotto, A.de Braud, F. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. Urol. Int., 2009, 82(2),196-202.
57. Nimeiri, H.S.; Oza, A.M.; Morgan, R.J.; Friberg, G.; Kasza, K.; Faoro, L.; Salgia, R.; Stadler, W.M.; Vokes, E.E.Fleming, G.F. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol., 2008, 110(1), 49-55.
58. Soulieres, D.; Senzer, N.N.; Vokes, E.E.; Hidalgo, M.; Agarwala, S.S.Siu, L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol., 2004, 22(1), 77-85.
59. Gravis, G.; Bladou, F.; Salem, N.; Goncalves, A.; Esterni, B.; Walz, J.; Bagattini, S.; Marcy, M.; Brunelle, S.Viens, P. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann. Oncol., 2008, 19(9), 1624-8.
60. Lestingi, T.M.; Tolzien, K.; Galvez, A.; Kelby, S.; Bitran, J.D.Nabhan, C. A phase II study with single agent erlotinib in chemotherapy-naïve androgen independent prostate cancer (AIPC) - abstr 16104. J. Clin. Oncol., 2008, 26.
61. Tambo, M.; Higashihara, E.; Terado, Y.; Nutahara, K.Okegawa, T. Comparison of serum Her-2/neu with immunohistochemical Her-2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int. J. Urol., 2009, 16(4), 369-74.
62. Domingo-Domenech, J.; Fernandez, P.L.; Filella, X.; Martinez-Fernandez, A.; Molina, R.; Fernandez, E.; Alcaraz, A.; Codony, J.; Gascon, P.Mellado, B. Serum Her-2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann. Oncol., 2008, 19(2), 269-75.
63. Nagasawa, J.; Mizokami, A.; Koshida, K.; Yoshida, S.; Naito, K.Namiki, M. Novel Her-2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int. J. Urol., 2006, 13(5), 587-92.
64. Rusnak, D.W.; Lackey, K.; Affleck, K.; Wood, E.R.; Alligood, K.J.; Rhodes, N.; Keith, B.R.; Murray, D.M.; Knight, W.B.; Mullin, R.J.Gilmer, T.M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther., 2001, 1(2), 85-94.
65. Nelson, M.H.Dolder, C.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother., 2006, 40(2), 261-9.
66. Rocchi, P.; Muracciole, X.; Fina, F.; Mulholland, D.J.; Karsenty, G.; Palmari, J.; Ouafik, L.; Bladou, F.Martin, P.M. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene, 2004, 23(56), 9111-9.
67. Chen, Y.; Wilding, G.; Gee, J.; DiPaola, R.; Pins, M.; Carducci, M.; Stein, M.; Bubley, G.Liu, G. A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA. J. Clin. Oncol., 2008, 26(May 20 suppl; abstr 517).
68. Sridhar, S.; Hotte, S.; Chin, J.; Hudes, G.; Gregg, R.; Pond, G.; Duan, L.; Trachtenberg, J.; Dancey, J.Moore, M. A Multicenter Phase II Study of Lapatinib in Hormone Sensitive Prostate Cancer (HSPC). Absr 261. in 2007 Prostate Cancer Symposium, 2007.
69. Whang, Y.; Moore, C.; Armstrong, A.; Rathmell, W.; Godley, P.; Crane, J.; Grigson, G.; Morris, K.; Watkins, C.George, D. A phase II trial of lapatinib in hormone refractory prostate cancer. J. Clin. Oncol., 2008, 26(15S May 20 Suppl), 16037.
70. Minkovsky, N.Berezov, A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs, 2008, 9(12), 1336-46.
71. Roth, G.J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem., 2009, 52(14), 4466-4480.
72. Hoekstra, R.; Dumez, H.; Eskens, F.A.; van der Gaast, A.; Planting, A.S.; de Heus, G.; Sizer, K.C.; Ravera, C.; Vaidyanathan, S.; Bucana, C.; Fidler, I.J.; van Oosterom, A.T.Verweij, J. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res., 2005, 11(19 Pt 1), 6908-15.
73. Mellinghoff, I.K.; Tran, C.Sawyers, C.L. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res., 2002, 62(18), 5254-9.
74. Kim, S.J.; Uehara, H.; Karashima, T.; Shepherd, D.L.; Killion, J.J.Fidler, I.J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin. Cancer Res., 2003, 9(3), 1200-10.
75. Allen, L.F.; Lenehan, P.F.; Eiseman, I.A.; Elliott, W.L.Fry, D.W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin. Oncol., 2002, 29(3 Suppl 11), 11-21.
76. Grunwald, V.Hidalgo, M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr. Probl. Cancer, 2002, 26(3), 109-64.
77. Ocana, A.; Serrano, R.; Calero, R.Pandiella, A. Novel tyrosine kinase inhibitors in the treatment of cancer. Curr. Drug Targets, 2009, 10(6), 575-6.
78. Mellinghoff, I.K.; Vivanco, I.; Kwon, A.; Tran, C.; Wongvipat, J.Sawyers, C.L. Her-2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 2004, 6(5), 517-27.
79. Hofer, M.D.; Fecko, A.; Shen, R.; Setlur, S.R.; Pienta, K.G.; Tomlins, S.A.; Chinnaiyan, A.M.Rubin, M.A. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia, 2004, 6(5), 503-12.
80. Kim, H.E.; Han, S.J.; Kasza, T.; Han, R.; Choi, H.S.; Palmer, K.C.Kim, H.R. Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. Int. J. Radiat. Oncol. Biol. Phys., 1997, 39(3), 731-6.
81. Pietras, K.; Sjoblom, T.; Rubin, K.; Heldin, C.H.Ostman, A. PDGF receptors as cancer drug targets. Cancer Cell, 2003, 3(5), 439-43.
82. Ko, Y.J.; Small, E.J.; Kabbinavar, F.; Chachoua, A.; Taneja, S.; Reese, D.; DePaoli, A.; Hannah, A.; Balk, S.P.Bubley, G.J. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin. Cancer Res., 2001, 7(4), 800-5.
83. Lin, A.M.; Rini, B.I.; Weinberg, V.; Fong, K.; Ryan, C.J.; Rosenberg, J.E.; Fong, L.Small, E.J. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int., 2006, 98(4), 763-9.
84. Bajaj, G.K.; Zhang, Z.; Garrett-Mayer, E.; Drew, R.; Sinibaldi, V.; Pili, R.; Denmeade, S.R.; Carducci, M.A.; Eisenberger, M.A.DeWeese, T.L. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology, 2007, 69(3), 526-31.
85. Rao, K.; Goodin, S.; Levitt, M.J.; Dave, N.; Shih, W.J.; Lin, Y.; Capanna, T.; Doyle-Lindrud, S.; Juvidian, P.DiPaola, R.S. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate, 2005, 62(2), 115-22.
86. Tiffany, N.M.; Wersinger, E.M.; Garzotto, M.Beer, T.M. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2004, 63(5), 934-9.
87. Kojima, S.; Inahara, M.; Suzuki, H.; Ichikawa, T.Furuya, Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int. J. Urol., 2009, 16(2), 161-7.
88. Rosen, C.J.; Pollak, M. Circulating IGF-I: new perspectives for a new century. Trends Endocrinol. Metab., 1999, 10(4), 136-141.
89. Roddam, A.W.; Allen, N.E.; Appleby, P.; Key, T.J.; Ferrucci, L.; Carter, H.B.; Metter, E.J.; Chen, C.; Weiss, N.S.; Fitzpatrick, A.; Hsing, A.W.; Lacey, J.V. Jr.; Helzlsouer, K.; Rinaldi, S.; Riboli, E.; Kaaks, R.; Janssen, J.A.; Wildhagen, M.F.; Schroder, F.H.; Platz, E.A.; Pollak, M.; Giovannucci, E.; Schaefer, C.; Quesenberry, C.P. Jr.; Vogelman, J.H.; Severi, G.; English, D.R.; Giles, G.G.; Stattin, P.; Hallmans, G.; Johansson, M.; Chan, J.M.; Gann, P.; Oliver, S.E.; Holly, J.M.; Donovan, J.; Meyer, F.; Bairati, I.Galan, P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med., 2008, 149(7), 461-71, W83-8.
90. Wetterau, L.A.; Francis, M.J.; Ma, L.Cohen, P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J. Clin. Endocrinol. Metab., 2003, 88(7), 3354-9.
91. Gentile, A.; Trusolino, L.Comoglio, P.M. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis. Rev., 2008, 27(1), 85-94.
92. Gentile, A.; D'Alessandro, L.; Lazzari, L.; Martinoglio, B.; Bertotti, A.; Mira, A.; Lanzetti, L.; Comoglio, P.M.; Medico, E. Met-driven invasive growth involves transcriptional regulation of Arhgap12. Oncogene, 2008 [Epub ahead of print].
93. Birchmeier, C.; Birchmeier, W.; Gherardi, E.Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 2003, 4(12), 915-25.
94. Knudsen, B.S.Edlund, M. Prostate cancer and the met hepatocyte growth factor receptor. Adv. Cancer Res., 2004, 91, 31-67.
95. Verras, M.; Lee, J.; Xue, H.; Li, T.H.; Wang, Y.Sun, Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res., 2007, 67(3), 967-75.
96. Qi, W.; Cooke, L.S.; Stejskal, A.; Riley, C.; Croce, K.D.; Saldanha, J.W.; Bearss, D.Mahadevan, D. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer, 2009, 9, 142.
97. Djakiew, D.; Delsite, R.; Pflug, B.; Wrathall, J.; Lynch, J.H.Onoda, M. Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. Cancer Res., 1991, 51(12), 3304-10.
98. Pflug, B.Djakiew, D. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol. Carcinog., 1998, 23(2), 106-14.
99. Miknyoczki, S.J.; Wan, W.; Chang, H.; Dobrzanski, P.; Ruggeri, B.A.; Dionne, C.A.Buchkovich, K. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin. Cancer Res., 2002, 8(6),1924-31.
100. Festuccia, C.; Muzi, P.; Gravina, G.L.; Millimaggi, D.; Speca, S.; Dolo, V.; Ricevuto, E.; Vicentini, C.Bologna, M. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int. J. Oncol., 2007, 30(1), 193-200.
101. Knapper, S.; Burnett, A.K.; Littlewood, T.; Kell, W.J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M.J.Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108(10), 3262-70.
102. Knapper, S.; Mills, K.I.; Gilkes, A.F.; Austin, S.J.; Walsh, V.Burnett, A.K. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood, 2006, 108(10), 3494-503.
103. Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.Denmeade, S.R. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol. Ther., 2007, 6(9), 1360-7.
104. George, D.J.; Dionne, C.A.; Jani, J.; Angeles, T.; Murakata, C.; Lamb, J.Isaacs, J.T. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res., 1999, 59(10), 2395-401.
105. Weeraratna, A.T.; Dalrymple, S.L.; Lamb, J.C.; Denmeade, S.R.; Miknyoczki, S.; Dionne, C.A.Isaacs, J.T. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin. Cancer Res., 2001, 7(8), 2237-45.
106. Posadas, E.M.; Al-Ahmadie, H.; Robinson, V.L.; Jagadeeswaran, R.; Otto, K.; Kasza, K.E.; Tretiakov, M.; Siddiqui, J.; Pienta, K.J.; Stadler, W.M.; Rinker-Schaeffer, C.Salgia, R. FYN is overexpressed in human prostate cancer. BJU Int., 2009, 103(2), 171-7.
107. Park, S.I.; Zhang, J.; Phillips, K.A.; Araujo, J.C.; Najjar, A.M.; Volgin, A.Y.; Gelovani, J.G.; Kim, S.J.; Wang, Z.Gallick, G.E. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res., 2008, 68(9), 3323-33.
108. de Vries, T.J.; Mullender, M.G.; van Duin, M.A.; Semeins, C.M.; James, N.; Green, T.P.; Everts, V.Klein-Nulend, J. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol. Cancer Res., 2009, 7(4), 476-88.
109. Yang, J.C.; Ok, J.H.; Busby, J.E.; Borowsky, A.D.; Kung, H.J.Evans, C.P. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res., 2009, 69(1), 151-60.
110. Chang, Y.M.; Bai, L.; Liu, S.; Yang, J.C.; Kung, H.J.Evans, C.P. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene, 2008, 27(49), 6365-75.
111. Lara, P.N. Jr.; Longmate, J.; Evans, C.P.; Quinn, D.I.; Twardowski, P.; Chatta, G.; Posadas, E.; Stadler, W.Gandara, D.R. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs, 2009, 20(3), 179-84.
112. Lombardo, L.J.; Lee, F.Y.; Chen, P.; Norris, D.; Barrish, J.C.; Behnia, K.; Castaneda, S.; Cornelius, L.A.; Das, J.; Doweyko, A.M.; Fairchild, C.; Hunt, J.T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G.L.; Schmidt, R.J.; Tokarski, J.; Wen, M.L.; Wityak, J.Borzilleri, R.M. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-yl-amino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem., 2004, 47(27), 6658-61.
113. Nam, S.; Kim, D.; Cheng, J.Q.; Zhang, S.; Lee, J.H.; Buettner, R.; Mirosevich, J.; Lee, F.Y.Jove, R. Action of the Src family kinase inhibitor,
114. Shor, A.C.; Keschman, E.A.; Lee, F.Y.; Muro-Cacho, C.; Letson, G.D.; Trent, J.C.; Pledger, W.J.Jove, R. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res., 2007, 67(6), 2800-8.
115. Araujo, J.; Armstrong, A.; Braud, E.; Posadas, E.; Lonberg, M.; Gallick, G.; Trudel, G.; Paliwal, P.; Agrawal, S.Logothetis, C. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J. Clin. Oncol., 2009, 27(15s Suppl), abstr 5061.
116. Adjei, A.; Cohen, R.; Kurzrock, R.; Gordon, G.; Hangauer, D.; Dyster, L.; Fetterly, G.; Barrientes, S.; Hong, D.Naing, A. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J. Clin. Oncol., 2009, 27,(15S (May 20 Suppl), 3511).
117. Hay, N.Sonenberg, N. Upstream and downstream of mTOR. Genes Dev., 2004, 18(16), 1926-45.
118. Morgan, T.M.; Koreckij, T.D.Corey, E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets, 2009, 9(2), 237-49.
119. McMenamin, M.E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.Sellers, W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 1999, 59(17), 4291-6.
120. Sircar, K.; Yoshimoto, M.; Monzon, F.A.; Koumakpayi, I.H.; Katz, R.L.; Khanna, A.; Alvarez, K.; Chen, G.; Darnel, A.D.; Aprikian, A.G.; Saad, F.; Bismar, T.A.; Squire, J.A. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol., 2009, 218(4), 505-13.
121. Mulholland, D.J.; Dedhar, S.; Wu, H.Nelson, C.C. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene, 2006, 25(3), 329-37.
122. Amato, R.J.; Jac, J.; Mohammad, T.; Saxena, S. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin. Genitourin. Cancer, 2008, 6(2), 97-102.
123. Cohen, L.A.Guan, J.L. Mechanisms of focal adhesion kinase regulation. Curr. Cancer Drug Targets, 2005, 5(8), 629-43.
124. Mitra, S.K.; Hanson, D.A.Schlaepfer, D.D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol., 2005, 6(1), 56-68.
125. Gabarra-Niecko, V.; Schaller, M.D.Dunty, J.M. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev., 2003, 22(4), 359-74.
126. Rovin, J.D.; Frierson, H.F. Jr.; Ledinh, W.; Parsons, J.T.Adams, R.B. Expression of focal adhesion kinase in normal and pathologic human prostate tissues. Prostate, 2002, 53(2), 124-32.
127. Slack-Davis, J.K.; Martin, K.H.; Tilghman, R.W.; Iwanicki, M.; Ung, E.J.; Autry, C.; Luzzio, M.J.; Cooper, B.; Kath, J.C.; Roberts, W.G.Parsons, J.T. Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem., 2007, 282(20), 14845-52.
128. Roberts, W.G.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; Coleman, K.; Yao, L.; Martinez-Alsina, L.; Lorenzen, M.; Berliner, M.; Luzzio, M.; Patel, N.; Schmitt, E.; LaGreca, S.; Jani, J.; Wessel, M.; Marr, E.; Griffor, M.Vajdos, F. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res., 2008, 68(6),1935-44.
129. Duran, I.; Hotte, S.J.; Hirte, H.; Chen, E.X.; MacLean, M.; Turner, S.; Duan, L.; Pond, G.R.; Lathia, C.; Walsh, S.; Wright, J.J.; Dancey, J.; Siu, L.L. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin. Cancer Res., 2007, 13(16), 4849-57.
130. Cumashi, A.; Tinari, N.; Rossi, C.; Lattanzio, R.; Natoli, C.; Piantelli, M.Iacobelli, S. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett., 2008, 270(2), 229-33.
131. Ma, J.Waxman, D.J. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin. Cancer Res., 2009, 15(2), 578-88.
132. Horti, J.; Widmark, A.; Stenzl, A.; Federico, M.H.; Abratt, R.P.; Sanders, N.; Pover, G.M.Bodrogi, I. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother. Radiopharm., 2009, 24(2), 175-80.
133. Kubler, H.R.; van Randenborgh, H.; Treiber, U.; Wutzler, S.; Battistel, C.; Lehmer, A.; Wagenpfeil, S.; Hartung, R.; Paul, R., In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate, 2005, 63(4), 385-94.
134. Mathew, P.; Thall, P.F.; Jones, D.; Perez, C.; Bucana, C.; Troncoso, P.; Kim, S.J.; Fidler, I.J.Logothetis, C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J. Clin. Oncol., 2004, 22(16), 3323-9.
135. Mathew, P.; Thall, P.F.; Bucana, C.D.; Oh, W.K.; Morris, M.J.; Jones, D.M.; Johnson, M.M.; Wen, S.; Pagliaro, L.C.; Tannir, N.M.; Tu, S.M.; Meluch, A.A.; Smith, L.; Cohen, L.; Kim, S.J.; Troncoso, P.; Fidler, I.J.Logothetis, C.J. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin. Cancer Res., 2007, 13(19), 5816-24.
136. Salzberg, M.; Rochlitz, C.; Morant, R.; Thalmann, G.; Pedrazzini, A.; Roggero, E.; Schonenberger, A.; Knuth, A.Borner, M. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie, 2007, 30(7), 355-60.
137. Mimeault, M.; Moore, E.; Moniaux, N.; Henichart, J.P.; Depreux, P.; Lin, M.F.Batra, S.K. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int. J. Cancer, 2006, 118(4), 1022-31.
138. Halabi, S.; Vogelzang, N.J.; Ou, S.S.; Owzar, K.; Archer, L.Small, E.J. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J. Clin. Oncol., 2009, 27(17), 2766-71.
139. Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol., 2008, 26(7), 1148-59.
140. Arteaga, C.L. HER3 and mutant EGFR meet MET. Nat. Med., 2007, 13(6), 675-7.
141. Sonpavde, G.; Hutson, T.E.; Berry, W.R.; Boehm, K.A.Asmar, L. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin. Genitourin Cancer, 2008, 6(2), 134-7.
142. Hu-Lowe, D.D.; Zou, H.Y.; Grazzini, M.L.; Hallin, M.E.; Wickman, G.R.; Amundson, K.; Chen, J.H.; Rewolinski, D.A.; Yamazaki, S.; Wu, E.Y.; McTigue, M.A.; Murray, B.W.; Kania, R.S.; O'Connor, P.; Shalinsky, D.R.; Bender, S.L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14(22), p, 7272-83.
143. Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Shibuya, M.Isae, T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res., 2006, 66(18), 9134-42.
144. Hurwitz, H.I.; Dowlati, A.; Saini, S.; Savage, S.; Suttle, A.B.; Gibson, D.M.; Hodge, J.P.; Merkle, E.M.Pandite, L. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res., 2009, 15(12), 4220-7.
145. Drevs, J.; Siegert, P.; Medinger, M.; Mross, K.; Strecker, R.; Zirrgiebel, U.; Harder, J.; Blum, H.; Robertson, J.; Jurgensmeier, J.M.; Puchalski, T.A.; Young, H.; Saunders, O.Unger, C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol., 2007, 25(21), 3045-54.
146. Eskens, F.A.; Mom, C.H.; Planting, A.S.; Gietema, J.A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.de Vries, E.G. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (Her-2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer, 2008, 98(1), 80-5.
147. Folprecht, G.; Tabernero, J.; Kohne, C.H.; Zacharchuk, C.; Paz-Ares, L.; Rojo, F.; Quinn, S.; Casado, E.; Salazar, R.; Abbas, R.; Lejeune, C.; Marimon, I.; Andreu, J.; Ubbelohde, U.; Cortes-Funes, H.Baselga, J. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin. Cancer Res., 2008, 14(1), 215-23.
148. Redaelli, S.; Piazza, R.; Rostagno, R.; Magistroni, V.; Perini, P.; Marega, M.; Gambacorti-Passerini, C.Boschelli, F. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol., 2009, 27(3), 469-71.
149. Hidalgo, M.; Buckner, J.C.; Erlichman, C.; Pollack, M.S.; Boni, J.P.; Dukart, G.; Marshall, B.; Speicher, L.; Moore, L.Rowinsky, E.K. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res., 2006, 12(19), 5755-63.
150. Hartford, C.M.; Desai, A.A.; Janisch, L.; Karrison, T.; Rivera, V.M.; Berk, L.; Loewy, J.W.; Kindler, H.; Stadler, W.M.; Knowles, H.L.; Bedrosian, C.Ratain, M.J. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res., 2009, 15(4), 1428-34.
151. Cetnar, J.; Rosen, M.; Vaughn, D.; Haas, N.; Troxel, A.; Song, H.; Adluru, G.; Flaherty, K.; O'Dwyer, P.Amaravadi, R. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol., 2009, 27 (Suppl), abstr e16055.
152. Mardjuadi, F.; Medioni, J.; Kerger, J.; Canon, J.L.; Duck, L.; Oudard, S.; Clausse, M.; D'Hondt, D.; Moxhon, A.Machiels, J.P. A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2009, 27(15s) Abstr 5153.
153. Zurita, A.J.; Liu, G.; Hutson, T.; Kozloff, M.; Shore, N.; Wilding, G.; Logothetis, C.J.; Chen, I.; Chow Maneval, E.George, D. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). J. Clin. Oncol., 2009, 27(15s Suppl.), abstr. 5166.
154. Chiorean, E.G.; Porter, J.M.; Foster, A.E.; Al Omari, A.S.; Yoder, C.A.; Fife, K.L.; Strother, R.M.; Murry, D.J.; Yu, M.; Jones, D.R.Sweeney, C.J. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin. Cancer Res., 2008, 14(4), 1131-7.
155. Wilding, G.; Soulie, P.; Trump, D.; Das-Gupta, A.Small, E. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer, 2006, 106(9), 1917-24.